Flecainide
- Generic Name
- Flecainide
- Brand Names
- Tambocor
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20F6N2O3
- CAS Number
- 54143-55-4
- Unique Ingredient Identifier
- K94FTS1806
- Background
Flecainide is a Class I anti-arrhythmic agent like encainide and propafenone. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.
Flecainide was granted FDA approval on 31 October 1985.
- Indication
In New Zealand and America, flecainide is indicated to prevent supraventricular arrhythmias and ventricular arrhythmias. In the United States, it is also indicated to prevent paroxysmal atrial fibrillation and flutter.
- Associated Conditions
- Atrial Fibrillation, Ventricular Tachycardia (VT), Severe Atrioventricular nodal reentrant tachycardia, Severe Paroxysmal atrial fibrillation, Severe Paroxysmal supraventricular tachycardia, Severe Supraventricular Tachycardias, Severe Sustained ventricular tachycardia, Severe ventricular arrhythmias
Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy
- Conditions
- Premature Ventricular BeatsPremature Ventricular ComplexesPremature Ventricular Contraction (PVC)Arrhythmia VentricularVentricular Dysfunction, LeftCardiomyopathiesVentricular DysfunctionCardiomyopathies, Secondary
- Interventions
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 300
- Registration Number
- NCT06949748
- Locations
- 🇬🇷
Cardiology Clinic, University Hospital of Patras, Patras, Achaia, Greece
🇬🇷1st Cardiology Clinic, National and Kapodistrian University of Athens, Athens, Attika, Greece
🇬🇷Cardilogy Clinic, University of Crete, Heraklion, Greece
N-of-1 in ATS and MEPPC
- Conditions
- Multifocal Ectopic Purkinje-related Premature ContractionsAndersen Tawil Syndrome
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-01-29
- Target Recruit Count
- 10
- Registration Number
- NCT06205550
Single Dose Flecainide for Early Sinus Rhythm Conversion of Perioperative Atrial Fibrillation After Noncardiac Surgery
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Population Health Research Institute
- Registration Number
- NCT06142604
Effect and Safety of Flecainide and Metoprolol Versus Metoprolol Alone to Suppress Ventricular Arrhythmias in Arrhythmic Mitral Valve Prolapse
- Conditions
- Ventricular Arrhythmias and Cardiac ArrestMitral Valve Prolapse
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05631730
- Locations
- 🇳🇴
Oslo University Hospital Rikshospitalet, Oslo, Norway
Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia
- Conditions
- Atrial Fibrillation ParoxysmalCoronary Artery Disease Without Residual Ischemia
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Hippocration General Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05549752
- Locations
- 🇬🇷
Athens Heart Center Amarousion, Athens, Attiki, Greece
🇬🇷Attikon General Hospital of Athens, Athens, Greece
🇬🇷First Department of Cardiology, Hippocration General Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
- Conditions
- Patent Foramen OvaleAtrial ArrhythmiaCryptogenic Stroke
- Interventions
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 186
- Registration Number
- NCT05213104
- Locations
- 🇫🇷
Hopital Pitié Salpetrière, Paris, IDF, France
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- InCarda Therapeutics, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05039359
- Locations
- 🇵🇱
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Toruń, Poland
🇺🇸Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS)
- Conditions
- Atrial FibrillationArrhythmias, Cardiac
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- AHEPA University Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT04991896
- Locations
- 🇬🇷
Skylitseio General Hospital, Chios, Greece
Shortening Duration of Antiarrhythmic Medication for SVT in Infants
- Conditions
- Supraventricular Tachycardia
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Tampere University Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04837261
- Locations
- 🇫🇮
Hämeenlinna Central Hospital, Hämeenlinna, Kanta-Häme, Finland
🇫🇮Sakunta Central Hospital, Pori, Satakunta, Finland
🇫🇮Central Finland Central Hospital, Jyväskylä, Central Finland, Finland
Elimination of VPB With Ablation Versus Anti-arrhythmic Drug Treatment
- Conditions
- Ventricular Premature Beats
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Maatschap Cardiologie Zwolle
- Target Recruit Count
- 22
- Registration Number
- NCT03845010
- Locations
- 🇳🇱
Isala hospital, Zwolle, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.